BC is also extremely variable in morphology and at the molecular level, necessitating combinatorial therapy modalities depending on the molecular subtype, which is defined by hormone receptor (HR) status and human epidermal growth factor receptor-2 (HER2) expression (Li et al., 2017; Kashyap et al., 2022). Here, ERBB2 is linked to breast cancer.